Aptose Biosciences Inc. (TSX:APS)
Canada · Delayed Price · Currency is CAD | Market Cap | 5.59M -21.8% |
| Revenue (ttm) | n/a |
| Net Income | -38.47M |
| EPS | -15.06 |
| Shares Out | 2.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Open | 2.200 |
| Previous Close | 2.330 |
| Day's Range | 2.190 - 2.200 |
| 52-Week Range | 1.020 - 2.590 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About Aptose Biosciences
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute ... [Read more]
News
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
SAN DIEGO and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement ...
Aptose Biosciences Earnings release: Q1 2026
Aptose Biosciences released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Aptose Biosciences Quarterly report: Q1 2026
Aptose Biosciences has published its Q1 2026 quarterly earnings report on May 13, 2026.
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 20
Aptose Biosciences Annual report: Q4 2025
Aptose Biosciences has published its Q4 2025 annual report on March 31, 2026.
Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
Shareholders are Recommended to Vote “FOR” the Aptose BiosciencesProposed Plan of Arrangement with Hanmi Pharmaceutical Shareholders are Reminded of Voting Deadline for Upcoming Special Meeting SAN DI...
Aptose Biosciences says ISS recommends shareholders vote for Hanmi arrangement
Aptose Biosciences (APTOF) announced that Institutional Shareholder Services has recommended that Aptose shareholders vote “FOR” a special resolution to approve the previously announced arrangement pu...
Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
Aptose Biosciences announces amendment to arrangement agreement
Aptose Biosciences (APTOF) entered into an amended and restated arrangement agreement dated February 23, 2026 amending and restating the arrangement agreement dated November 18, 2025, pursuant to whic...
Aptose Biosciences Proxy statement: Proxy Filing
Aptose Biosciences filed a proxy statement on February 24, 2026, providing details for shareholder voting and corporate governance matters.
Aptose Biosciences Proxy statement: Proxy Filing
Aptose Biosciences filed a proxy statement on February 17, 2026, providing details for shareholder voting and corporate governance matters.
Aptose Biosciences Proxy statement: Proxy Filing
Aptose Biosciences filed a proxy statement on February 9, 2026, providing details for shareholder voting and corporate governance matters.
Aptose Biosciences Proxy statement: Proxy Filing
Aptose Biosciences filed a proxy statement on January 15, 2026, providing details for shareholder voting and corporate governance matters.
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
SAN DIEGO and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) announced today that it will be rescheduling its upcoming special me...
Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
Aptose's Tuspetinib Triple Drug Therapy Featured at 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Population
Aptose Biosciences Proxy statement: Proxy Filing
Aptose Biosciences filed a proxy statement on December 5, 2025, providing details for shareholder voting and corporate governance matters.
Aptose Biosciences downgraded to Neutral from Buy at Alliance Global
Alliance Global downgraded Aptose Biosciences (APTOF) to Neutral from Buy with a C$2.41 price target The firm does not expect better offer than the Hanmi tender.
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
SAN DIEGO and TORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) and Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) today announced that Apt...
Aptose Reports Third Quarter 2025 Results
Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose Levels Patients are Now B...
Aptose Biosciences Earnings release: Q3 2025
Aptose Biosciences released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.
Aptose Biosciences Quarterly report: Q3 2025
Aptose Biosciences has published its Q3 2025 quarterly earnings report on November 13, 2025.
Aptose's Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher dose levels of 80 mg and 120 mg TUS, exceeding the 66% rate expected from VEN+AZA alone CR/CRh re...
Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
SAN DIEGO and TORONTO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib...
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 10...
Aptose Reports Second Quarter 2025 Results
Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at 120 mg Dose Cohort Safety Review Committ...